Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment

sCD40L-caspase 3 chimeric protein for treating B-cell malignancies

Authors

  • Rotem Kedar MD, PhD,

    1. Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel
    Search for more papers by this author
  • Ofra Sabag PhD,

    1. Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel
    Search for more papers by this author
  • Michal Licthenstein PhD,

    1. Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel
    Search for more papers by this author
  • Haya Lorberboum-Galski PhD

    Corresponding author
    1. Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel
    • Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem 91120, Israel

    Search for more papers by this author
    • Fax: (011) 972-2-64158485


Abstract

BACKGROUND:

A wide range of hematologic malignancies arises from numerous cell types. In an attempt to offer a new target for treating B-cell malignancies, in this study, the authors tested the possibility of using the CD40/CD40L system as a common targeting system for the various malignancies in this group.

METHODS:

Two chimeric proteins, soluble CD40 ligand (sCD40L)-caspase 3 (sCD40L-l-Caspase3) and sCD40L-pseudomonas exotoxin 38 (PE38) (sCD40L-l-PE38), were constructed, expressed, and partially purified. The ability of the chimeric proteins to kill tumor cells that expressed CD40 was tested by using proliferation assays. In addition, the induction of apoptosis in treated cells was followed by measuring expression levels of apoptotic proteins using real-time polymerases chain reaction analysis, caspase 3 enzymatic activity, and tracking changes in the cell cycle with fluorescence-activated cell-sorting analysis.

RESULTS:

The chimeric proteins exhibited concentration-dependent and time-dependent killing ability. The new chimeric proteins had no effect in several carcinoma cell lines that did not express the CD40 receptor. Treating tumor cells with sCD40L-based chimeric proteins led to internalization of the fusion proteins into the cell cytoplasm of B cells. Shortly after treatment, a sharp rise in B-cell chronic lymphocytic leukemia/lymphoma 2 (Bcl2) expression levels occurred. Approximately 36 hours after the initiation of treatment, Bcl2 levels dropped, whereas Bcl2-associated X protein (Bax) expression levels rose, pushing the cells toward apoptosis. Concomitantly, caspase 3 RNA levels rose.

CONCLUSIONS:

sCD40L-based chimeric proteins were able to bind and internalize into B cells that expressed the CD40 receptor and specifically and efficiently induced apoptotic death. Moreover, the current results validated for the first time the ability of sCD40L to serve as a direct delivery system for targeted molecules. sCD40L-based chimeric cytotoxic proteins offer a new weapon in the everlasting war against cancer. Cancer 2012. © 2012 American Cancer Society.

Ancillary